Study of N91115 in Patients With Cystic Fibrosis Homozygous F508del-CFTR Mutation

PHASE1CompletedINTERVENTIONAL
Enrollment

51

Participants

Timeline

Start Date

February 28, 2015

Primary Completion Date

July 31, 2015

Study Completion Date

July 31, 2015

Conditions
Cystic Fibrosis
Interventions
DRUG

N91115

S Nitrosoglutathione Reductase Inhibitor

Trial Locations (19)

10032

Columbia University, New York

The New York Presbyterian Hospital, Columbia University Medical Center, New York

19104

Children's Hospital of Philadelphia, Philadelphia

21287

Johns Hopkins Hospital, Baltimore

27599

University of North Carolina, Chapel Hill

35294

University of Alabama @ Birmingham, Birmingham

43205

Nationwide Children's Hospital, Columbus

44106

Rainbow Babies and Children's Hospital - Case Medical Center, Cleveland

45229

Cincinnati Children's Hospital, Cincinnati

46202

Indiana University, Indianapolis

52242

University of Iowa Children's Hospital, Iowa City

55455

University of Minnesota, Minneapolis

60611

Northwestern University, Chicago

63110

Washington University, St Louis

80045

Children's CO, Aurora

80206

National Jewish Health, Denver

94304

Stanford University, Palo Alto

98105

Seattle Children's Hospital, Seattle

02115

Boston Children's Hospital, Boston

Sponsors
All Listed Sponsors
lead

Nivalis Therapeutics, Inc.

INDUSTRY

NCT02275936 - Study of N91115 in Patients With Cystic Fibrosis Homozygous F508del-CFTR Mutation | Biotech Hunter | Biotech Hunter